Clinical Features and Risk Factors for Mortality in Hospitalized Older Adults with Pneumonia

Table 1

Patient characteristics.

	Vaccinated	Unvaccinated	value
	n = 38 (%)	n = 55 (%)
Demographics
Age, median (IQR)	81 (74–84)	80 (71–87)	0.94
Males	23 (60.5)	31 (56.3)	0.69
Females	15 (39.5)	24 (43.6)	0.69
PS, median (IQR)	1 (0–2)	1 (0–3)	0.25
HCAP	4 (10.5)	13 (23.6)	0.10
Vaccination against influenza	33 (86.8)	15 (27.3)	<0.001
Comorbid conditions
Hypertension	12 (31.6)	18 (32.8)	0.91
Diabetes	6 (15.8)	7 (12.7)	0.68
Heart disease	15 (39.5)	13 (23.6)	0.1
Kidney disease	3 (7.9)	7 (12.7)	0.46
Neurological disease	6 (15.8)	13 (23.6)	0.36
Cancer	7 (18.4)	5 (9.1)	0.19
Respiratory disease	26 (68.4)	27 (49.1)	0.06
Types of pneumococcal vaccine
PPV23	27 (71.1)
PCV13	2 (5.2)
PPV23 + PCV13	1 (2.6)
Unknown	8 (21.1)
Time after PPV23 vaccination
<5 years	21 (75.0)
>5 years	6 (21.4)
Unknown	1 (2.6)

IQR: interquartile range; PS: performance status; HCAP: healthcare-associated pneumonia; PPV23: 23-valent pneumococcal polysaccharide vaccine; PCV13: 13-valent pneumococcal conjugate vaccine.